Exact Mass: 922.4761

Exact Mass Matches: 922.4761

Found 17 metabolites which its exact mass value is equals to given mass value 922.4761, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Lyciumoside VI

2-[(6-{[(2E,6Z,10E)-14-{[3,4-dihydroxy-6-(hydroxymethyl)-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl]oxy}-2,6,10,14-tetramethylhexadeca-2,6,10,15-tetraen-1-yl]oxy}-3,4,5-trihydroxyoxan-2-yl)methoxy]-6-methyloxane-3,4,5-triol

C44H74O20 (922.4773)


Constituent of Lycium chinense (Chinese boxthorn). Lyciumoside VI is found in tea, coffee and coffee products, and herbs and spices. Lyciumoside VI is found in coffee and coffee products. Lyciumoside VI is a constituent of Lycium chinense (Chinese boxthorn).

   

Capsianoside VI

2-({6-[(3,5-dihydroxy-2-methyl-6-{[(2E,6Z,10E)-2,6,10,14-tetramethyl-14-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}hexadeca-2,6,10,15-tetraen-1-yl]oxy}oxan-4-yl)oxy]-3,4,5-trihydroxyoxan-2-yl}methoxy)-6-methyloxane-3,4,5-triol

C44H74O20 (922.4773)


Constituent of Capsicum annuum. Capsianoside VI is found in many foods, some of which are yellow bell pepper, green bell pepper, orange bell pepper, and herbs and spices. Capsianoside VI is found in herbs and spices. Capsianoside VI is a constituent of Capsicum annuum.

   

PGP(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z))

[(2S)-3-({[(2R)-3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyloxy]-2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C48H76O13P2 (922.4761)


PGP(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z)) is a phosphatidylglycerophosphate (PGP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site followed by another phosphate moiety. Phosphatidylglycerolphosphate is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant (up to 11\\% of the total). It is well established that the concentration of phosphatidylglycerolphosphate increases during fetal development. Phosphatidylglycerolphosphate may be present in animal tissues merely as a precursor for cardiolipin synthesis. As is the case with diacylglycerols, phosphatidylglycerophosphates can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PGP(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of docosahexaenoic acid at the C-1 position and one chain of eicosatetraenoic acid at the C-2 position. They are synthesized by the addition of glycerol 3-phosphate to a CDP-diacylglycerol. In turn, PGPs are dephosphorylated to phosphatidylglycerols (PGs). While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes.

   

PGP(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

[(2S)-3-({[(2R)-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyloxy]-3-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C48H76O13P2 (922.4761)


PGP(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) is a phosphatidylglycerophosphate (PGP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site followed by another phosphate moiety. Phosphatidylglycerolphosphate is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant (up to 11\\% of the total). It is well established that the concentration of phosphatidylglycerolphosphate increases during fetal development. Phosphatidylglycerolphosphate may be present in animal tissues merely as a precursor for cardiolipin synthesis. As is the case with diacylglycerols, phosphatidylglycerophosphates can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PGP(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of arachidonic acid at the C-1 position and one chain of docosahexaenoic acid at the C-2 position. They are synthesized by the addition of glycerol 3-phosphate to a CDP-diacylglycerol. In turn, PGPs are dephosphorylated to phosphatidylglycerols (PGs). While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes.

   

PGP(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z))

[(2S)-3-({[(2R)-3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyloxy]-2-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C48H76O13P2 (922.4761)


PGP(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)) belongs to the class of glycerophosphoglycerophosphates, also called phosphatidylglycerophosphates (PGPs). These lipids contain a common glycerophosphate skeleton linked to at least one fatty acyl chain and a glycero-3-phosphate moiety. As is the case with diacylglycerols, phosphatidylglycerophosphates can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions. PGP(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)), in particular, consists of one 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl chain to the C-1 atom, and one 5Z,8Z,11Z,14Z-eicosatetraenoyl to the C-2 atom. In E. coli, PGPs can be found in the cytoplasmic membrane. The are synthesized by the addition of glycerol 3-phosphate to a CDP-diacylglycerol. In turn, PGPs are dephosphorylated to Phosphatidylglycerols (PGs) by the enzyme Phosphatidylglycerophosphatase.

   
   

3-O-alpha-L-rhamnopyranosyl-(1->4)-beta-D-glucopyranosyl-17-hydroxygeranyllinalool-17-O-alpha-L-rhamnopyranosyl-(1->4)-beta-D-glucopyranoside

3-O-alpha-L-rhamnopyranosyl-(1->4)-beta-D-glucopyranosyl-17-hydroxygeranyllinalool-17-O-alpha-L-rhamnopyranosyl-(1->4)-beta-D-glucopyranoside

C44H74O20 (922.4773)


   

Hexsose-deoxyHexose + Hexsose-deoxyHexose + C20H32

Hexsose-deoxyHexose + Hexsose-deoxyHexose + C20H32

C44H74O20 (922.4773)


Annotation level-3

   

Lyciumoside VI

2-{[(2E,6Z,10E)-14-{[3,4-dihydroxy-6-(hydroxymethyl)-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl]oxy}-2,6,10,14-tetramethylhexadeca-2,6,10,15-tetraen-1-yl]oxy}-6-{[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]methyl}oxane-3,4,5-triol

C44H74O20 (922.4773)


   

Capsianside VI

2-{[(6E,10Z,14E)-16-({3,5-dihydroxy-6-methyl-4-[(3,4,5-trihydroxy-6-{[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]methyl}oxan-2-yl)oxy]oxan-2-yl}oxy)-3,7,11,15-tetramethylhexadeca-1,6,10,14-tetraen-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C44H74O20 (922.4773)


   
   

2-({3,5-dihydroxy-2-methyl-6-[(2,6,10,14-tetramethyl-14-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}hexadeca-2,6,10,15-tetraen-1-yl)oxy]oxan-4-yl}oxy)-6-{[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]methyl}oxane-3,4,5-triol

2-({3,5-dihydroxy-2-methyl-6-[(2,6,10,14-tetramethyl-14-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}hexadeca-2,6,10,15-tetraen-1-yl)oxy]oxan-4-yl}oxy)-6-{[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]methyl}oxane-3,4,5-triol

C44H74O20 (922.4773)


   

(2s,3r,4s,5s,6r)-2-{[(2s,3s,4r,5r,6r)-3,5-dihydroxy-2-methyl-6-{[(2z,6e,10e,14s)-2,6,10,14-tetramethyl-14-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}hexadeca-2,6,10,15-tetraen-1-yl]oxy}oxan-4-yl]oxy}-6-({[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxane-3,4,5-triol

(2s,3r,4s,5s,6r)-2-{[(2s,3s,4r,5r,6r)-3,5-dihydroxy-2-methyl-6-{[(2z,6e,10e,14s)-2,6,10,14-tetramethyl-14-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}hexadeca-2,6,10,15-tetraen-1-yl]oxy}oxan-4-yl]oxy}-6-({[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxane-3,4,5-triol

C44H74O20 (922.4773)


   

(2r)-2-{[(10e,12e)-1,17-dihydroxy-9-oxooctadeca-10,12-dien-1-ylidene]amino}-n-[(6r,9r,16s,17r)-5,8,11,15-tetrahydroxy-6-(hydroxymethyl)-9-(1h-indol-3-ylmethyl)-17-methyl-2-oxo-1-oxa-4,7,10,14-tetraazacycloheptadeca-4,7,10,14-tetraen-16-yl]pentanediimidic acid

(2r)-2-{[(10e,12e)-1,17-dihydroxy-9-oxooctadeca-10,12-dien-1-ylidene]amino}-n-[(6r,9r,16s,17r)-5,8,11,15-tetrahydroxy-6-(hydroxymethyl)-9-(1h-indol-3-ylmethyl)-17-methyl-2-oxo-1-oxa-4,7,10,14-tetraazacycloheptadeca-4,7,10,14-tetraen-16-yl]pentanediimidic acid

C46H66N8O12 (922.48)


   

2-({6-[(14-{[3,4-dihydroxy-6-(hydroxymethyl)-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl]oxy}-2,6,10,14-tetramethylhexadeca-2,6,10,15-tetraen-1-yl)oxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl}oxy)-6-methyloxane-3,4,5-triol

2-({6-[(14-{[3,4-dihydroxy-6-(hydroxymethyl)-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl]oxy}-2,6,10,14-tetramethylhexadeca-2,6,10,15-tetraen-1-yl)oxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl}oxy)-6-methyloxane-3,4,5-triol

C44H74O20 (922.4773)


   

(2s,3r,4r,5r,6s)-2-{[(2r,3s,4r,5r,6r)-6-{[(2z,6e,10e,14s)-14-{[(2s,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-2,6,10,14-tetramethylhexadeca-2,6,10,15-tetraen-1-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

(2s,3r,4r,5r,6s)-2-{[(2r,3s,4r,5r,6r)-6-{[(2z,6e,10e,14s)-14-{[(2s,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-2,6,10,14-tetramethylhexadeca-2,6,10,15-tetraen-1-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

C44H74O20 (922.4773)


   

2-{[(10e,12e)-1,17-dihydroxy-9-oxooctadeca-10,12-dien-1-ylidene]amino}-n-[5,8,11,15-tetrahydroxy-6-(hydroxymethyl)-9-(1h-indol-3-ylmethyl)-17-methyl-2-oxo-1-oxa-4,7,10,14-tetraazacycloheptadeca-4,7,10,14-tetraen-16-yl]pentanediimidic acid

2-{[(10e,12e)-1,17-dihydroxy-9-oxooctadeca-10,12-dien-1-ylidene]amino}-n-[5,8,11,15-tetrahydroxy-6-(hydroxymethyl)-9-(1h-indol-3-ylmethyl)-17-methyl-2-oxo-1-oxa-4,7,10,14-tetraazacycloheptadeca-4,7,10,14-tetraen-16-yl]pentanediimidic acid

C46H66N8O12 (922.48)